Retatrutide 20mg

Description

Strength: 20mg
CAS: 2381089-83-2
Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4845.444 g/mol
Peptide Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
Synonyms: Retatrutide acetate, LY3437943
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Retatrutide 20mg is a research-grade synthetic peptide consisting of a 39-amino-acid core with a C20 fatty diacid moiety. The molecular formula is C₂₂₁H₃₄₂N₄₆O₆₈, with a molar mass of 4731 g/mol and an approximate molecular weight of ~4992.6 Da (accounting for the fatty acid modification).

It comes as a lyophilized powder at ≥98% purity. Aside from the 20 mg vial, researchers may also buy Retatrutide in a Retatrutide 10 mg vial.

Retatrutide for research has been studied for its effects on metabolic regulation, energy balance, nutrient signaling, and multi-pathway hormone activity, strictly in laboratory environments.

• High-purity (≥98%) retatrutide peptide suitable for controlled laboratory studies
• Supplied as a stable lyophilized powder for long-term storage and flexible reconstitution
• Available in a 20mg format; also offered as a Retatrutide 10 mg vial for dose-range experiments
• Has been studied for its triple-agonist activity on GIP, GLP-1, and glucagon-related pathways
• Useful for metabolic, endocrine, and receptor-signaling research
• Packaged in sterile, sealed vials to maintain sample integrity
• Compatible with standard buffers such as sterile water or PBS (pH 7.4)

Retatrutide is of interest due to its ability to activate multiple metabolic receptors simultaneously. Research has shown:

Receptor Potency (EC₅₀ values)

• GIP receptor: ~0.0643 nM (highest potency)
• GLP-1 receptor: ~0.775 nM
• Glucagon receptor: ~5.79 nM

This balanced activation profile allows researchers to examine:

• Energy balance and glucose homeostasis
• Gastric emptying delay and nutrient handling
• Insulin secretion dynamics in response to glucose
• Body-composition regulation, including fat-related signaling
• Lipolysis and hepatic glucose output in metabolic models
• Multi-pathway co-agonist interactions and receptor synergy

Retatrutide for research is widely used in in vitro, in vivo, and early-phase trial models to study complex hormonal signaling patterns without implying therapeutic outcomes.

Typical Research Dose Ranges

• Weekly doses between 4 mg and 12 mg in early-phase human studies
• Common study groups: 1 mg, 4 mg, 8 mg, and 12 mg
• The 20mg formulation allows researchers to prepare custom aliquots and mid-range dosing

Dose-Escalation Protocols

Research protocols often use stepwise escalation, such as:

• 2mg → 4mg → 8mg → 12mg weekly
• Some extended studies test intermediate or exploratory doses

Observed Research Findings

Across controlled settings, investigators have measured:

• Changes in metabolic biomarkers
• Modulation of receptor activity
• Alterations in energy expenditure and glucose signaling
• Shifts in appetite-related pathways

These outcomes remain specific to laboratory and early-phase research and do not imply therapeutic use.

Adverse Events Noted in Studies

Retatrutide has been associated with dose-dependent gastrointestinal side effects in Phase 2 and early Phase 3 trials:

• Nausea: Most frequently reported GI effect; increased with dose escalation; generally mild-to-moderate and transient
• Vomiting: Less common than nausea; primarily during dose escalation phases
• ​Diarrhea: Reported in escalation cohorts; manageable with dose adjustment
• Constipation: Documented at higher doses (8–12 mg); dose-dependent
• Abdominal discomfort: Mild-to-moderate; resolved after stabilization
• Key Finding: With proper dose escalation protocols (starting at 1 mg and titrating over 16–20 weeks), 85–90% of trial participants completed the full protocol without discontinuation. Most side effects resolved within 2–4 weeks after reaching a stable dose.

Storage (Lyophilized)

• Store unopened vials at 2–8°C for routine use; for long-term archival storage beyond 24 months, storage at –20°C is acceptable
• Protect from light and moisture
• Keep vial sealed until use

Reconstitution

• Reconstitute using sterile water or PBS (pH 7.4)
• Typical stock: 1 mg/mL
• Gently swirl; avoid vigorous shaking

Stability

• At 4°C: Use within 24–48 hours
• At –20°C: Stable for up to 2 weeks when aliquoted
• Avoid repeated freeze–thaw cycles

Safety

• Intended only for trained laboratory personnel
• Use gloves, sterile tools, and eye protection
• Dispose of unused material according to institutional chemical-safety protocols

References

https://pubmed.ncbi.nlm.nih.gov/40291085/

https://www.nature.com/articles/s41591-024-03018-2

https://pmc.ncbi.nlm.nih.gov/articles/PMC10844714/

https://pubmed.ncbi.nlm.nih.gov/38367045/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.